Posts

RA Capital Launches Rare Disease Company Oak Hill Bio onto Nasdaq via SPAC

on

GHO Capital and CBC Group to merge into world’s largest dedicated healthcare investor

on

Metsera Calls Pfizer's Threats 'Nonsense' as Rift Between Companies Widens

on

Novartis CEO on $12B Avidity Deal: 'Could Have Been Twice as Big'

on

Y-mAbs Therapeutics Acquired by SERB Pharmaceuticals in $412 Million Buyout Following Strategic Review

on

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

on

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

on

Acelyrin Rebuffs Concentra's Acquisition Bid, Reaffirms Commitment to Alumis Merger

on

BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger

on

Concentra's Surprise Bid Disrupts Acelyrin-Alumis Merger Plans

on